John J. Harrington Sells 7,500 Shares of Athersys, Inc. (NASDAQ:ATHX) Stock

Athersys, Inc. (NASDAQ:ATHX) EVP John J. Harrington sold 7,500 shares of the firm’s stock in a transaction that occurred on Monday, December 18th. The shares were sold at an average price of $1.77, for a total transaction of $13,275.00. Following the completion of the sale, the executive vice president now owns 658,474 shares in the company, valued at $1,165,498.98. The transaction was disclosed in a document filed with the SEC, which is available at this link.

Shares of Athersys, Inc. (NASDAQ:ATHX) opened at $1.96 on Friday. The firm has a market cap of $232.33, a price-to-earnings ratio of -7.54 and a beta of -0.38. Athersys, Inc. has a one year low of $1.02 and a one year high of $2.63.

A number of research analysts recently issued reports on the stock. ValuEngine upgraded shares of Athersys from a “sell” rating to a “hold” rating in a report on Friday, September 15th. Zacks Investment Research lowered shares of Athersys from a “buy” rating to a “hold” rating in a report on Tuesday, October 10th. Finally, Maxim Group set a $12.00 price target on shares of Athersys and gave the stock a “buy” rating in a report on Thursday, November 16th. One research analyst has rated the stock with a sell rating, one has assigned a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $7.17.

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. raised its stake in shares of Athersys by 9.4% during the 2nd quarter. Vanguard Group Inc. now owns 4,265,772 shares of the biopharmaceutical company’s stock worth $6,441,000 after purchasing an additional 366,572 shares during the period. State Street Corp raised its stake in shares of Athersys by 27.2% during the 2nd quarter. State Street Corp now owns 1,432,695 shares of the biopharmaceutical company’s stock worth $2,161,000 after purchasing an additional 305,944 shares during the period. Northern Trust Corp raised its stake in shares of Athersys by 30.8% during the 2nd quarter. Northern Trust Corp now owns 1,123,870 shares of the biopharmaceutical company’s stock worth $1,697,000 after purchasing an additional 264,549 shares during the period. Geode Capital Management LLC raised its stake in shares of Athersys by 35.2% during the 1st quarter. Geode Capital Management LLC now owns 756,004 shares of the biopharmaceutical company’s stock worth $1,292,000 after purchasing an additional 196,981 shares during the period. Finally, Mckinley Capital Management LLC Delaware bought a new stake in shares of Athersys during the 3rd quarter worth $1,093,000. 21.01% of the stock is currently owned by hedge funds and other institutional investors.

COPYRIGHT VIOLATION WARNING: “John J. Harrington Sells 7,500 Shares of Athersys, Inc. (NASDAQ:ATHX) Stock” was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this piece on another website, it was stolen and republished in violation of US & international trademark & copyright laws. The correct version of this piece can be accessed at https://www.dispatchtribunal.com/2018/01/12/athersys-inc-athx-evp-john-j-harrington-sells-7500-shares-of-stock.html.

About Athersys

Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.

Insider Buying and Selling by Quarter for Athersys (NASDAQ:ATHX)

Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply